Related Experiment Video
Updated: Apr 5, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains
Mark D Gonzalez1, Meghan A Wallace1, Tiffany Hink2
1Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract:
Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial DNA Synthesis
Antibiotic Selection
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis

